Lupin Launches Ajaduo M Forte, a Triple Fixed-Dose Combination of Empagliflozin, Linagliptin, and Metformin Extended Release (ER)

The product will be available in two strengths:

• Ajaduo M Forte 25: Empagliflozin 25 mg + Linagliptin 5 mg + Metformin ER 1000 mg at 21 Rs/ Tab
• Ajaduo M Forte 10: Empagliflozin 10 mg + Linagliptin 5 mg + Metformin ER 1000 mg at 19 Rs/Tab

Empagliflozin, an SGLT2 inhibitor, promotes urinary glucose excretion and offers cardiovascular and renal benefits. Linagliptin, a DPP-4 inhibitor, enhances incretin levels to improve insulin secretion and reduce glucagon release. Metformin ER improves insulin sensitivity and suppresses hepatic glucose production.

With its focused Fixed dose combinations, Ajaduo M Forte specifically targets multiple pathophysiological defects described in the Ominous Octet model, addressing key contributors such as insulin resistance, beta-cell dysfunction, and increased renal glucose reabsorption. It is the only USFDA-approved fixed-dose triple combination of Empagliflozin, Linagliptin, and Metformin, providing a comprehensive approach to glycemic control. The formulation aligns with globally recognized guidelines, including those issued by the ADA/EASD and RSSDI, reinforcing its clinical relevance and utility in modern diabetes management.